drugset / Trial / NCT01867866

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

NCT01867866

Phase 1 Completed 44 enrolled Taiho Oncology, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as a component of TAS-102 with FTD alone.

Timeline

Start
2013-05
Primary completion
2013-10
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TAS-102 Small molecule 35 mg/m2 Oral
Subject Trifluridine Small molecule 35 mg/m2 Oral

Indications